8-K current report · filed Nov 4, 2026

McKesson Corporation (MCK) 8-K Current Report: November 4, 2026

Item 2.02Item EX-99.1MCK overview

Short answer

McKesson Corporation (MCK) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Preliminary quarterly results for quarter ended September 30, 2026.

McKesson Corporation 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Preliminary quarterly results for quarter ended September 30, 2026
  • Results available in Exhibit 99.1 for detailed financial metrics and management commentary

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $111.0B, up 8%, with adjusted EPS $11.68, up 18%, signaling strong operating momentum
  • Free cash flow $2.9B and $3.6B returned to shareholders year-to-date, including $3.4B in repurchases
  • FY27 adjusted EPS guidance raised to $45.60-$46.40 from $44.20-$45.00, implying 17%-19% growth
  • North American Pharmaceutical adjusted operating profit rose 22% to $1.0B, while Medical-Surgical Solutions declined 10% to $225M
  • Planned $1.4B investment for approximately 49% of Option Care Health expands specialty-care exposure, pending approvals

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other McKesson Corporation 8-K filings

Get the next MCK 8-K as it lands

Follow MCK for push alerts, or ask the research agent what this filing means.